Celsius Inc. (NASDAQ: CELH): Stephens started coverage with an Overweight rating and a $180 target price. The posted consensus target is $146.55. Friday’s final trade was reported at $150.10 a share.
Clorox Co. (NYSE: CLX): Zacks named this as its Bull of the Day stock. The analyst says it is more of an earnings growth story than a revenue growth story. Shares last closed at $156.14, which is up more than 11% year to date.
Fiserv Inc. (NASDAQ: FISV): B. Riley Securities initiated coverage with a Buy rating and a $148 price objective. The consensus target is $133.22, and the shares closed on Friday at $114.23.
Fortune Brands Innovations Inc. (NYSE: FBIN): J.P. Morgan resumed coverage with a Neutral rating. The firm also trimmed its $73 target price to $70, bringing it more in line with the $70.40 consensus target. Friday’s closing share price was $67.57.
Hain Celestial Group Inc. (NASDAQ: HAIN): Stephens started coverage with an Overweight rating and a $17 target price. The posted consensus target is $146.00. The final trade for Friday was reported at $150.10 a share.
Moderna Inc. (NASDAQ: MRNA): Though UBS upgraded the stock to Buy from Neutral, its $221 target price was reduced to $191. The consensus target is $197.49, and the shares closed on Friday at $118.50.
Planet Fitness Inc. (NASDAQ: PLNT): Exane BNP Paribas downgraded the shares from Neutral to Underperform with a $57 target price. The consensus target is $87.00. The stock closed over 3% lower on Friday at $65.70 due to the downgrade and the weak tape.
Principal Financial Group Inc. (NASDAQ: PFG): Jefferies upgraded the insurance and investment heavyweight to Hold from Underperform. Its $60 target price rose to $65 as well, but the consensus target is higher at $75.33. The close on Friday was at $72.40 a share.
Reinsurance Group of America Inc. (NYSE: RGA): Jefferies downgraded the stock to Hold from Buy and cut its $170 target price to $160. The consensus target is up at $169.08, and Friday’s close at $139.41 a share.
Sarepta Therapeutics Inc. (NASDAQ: SRPT): Evercore ISI downgraded the shares from Outperform to In line with a $139 target price. The consensus target is $174.26. On Friday, shares closed at $114.09, which was down close to 8% for the day despite a positive ruling from the FDA.
Sponsored: Find a Qualified Financial Advisor
Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.
